Central Pharmaceuticals (DHA:CENTRALPHL) Other Current Payables: BDT6.82 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
65 GF Score
Price BDT10.60
GF Value BDT12.11
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Central Pharmaceuticals Other Current Payables?

Central Pharmaceuticals DHA:CENTRALPHL 65 Other Current Payables is BDT6.82 Mil as of Mar. 2026. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 65/100 and a GF Value™ of BDT12.11 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Central Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was BDT6.82 Mil.

Central Pharmaceuticals's quarterly Other Current Payables stayed the same from Sep. 2025 (BDT6.82 Mil) to Dec. 2025 (BDT6.82 Mil) but then increased from Dec. 2025 (BDT6.82 Mil) to Mar. 2026 (BDT6.82 Mil).

Central Pharmaceuticals's annual Other Current Payables declined from Jun. 2023 (BDT6.82 Mil) to Jun. 2024 (BDT6.82 Mil) but then stayed the same from Jun. 2024 (BDT6.82 Mil) to Jun. 2025 (BDT6.82 Mil).

Central Pharmaceuticals Other Current Payables Related Terms

Central Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Central Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceuticals Other Current Payables Chart

Central Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.83 6.82 6.82 6.82 6.82

Central Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.82 6.82 6.82 6.82
DHA:CENTRALPHL
65GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of BDT6.82 Mil mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a Other Current Payables of BDT6.82 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' Other Current Payables too high?
Central Pharmaceuticals' current Other Current Payables is BDT6.82 Mil. Overall, Central Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Other Current Payables compare to ZTS and UTHR?
Central Pharmaceuticals' Other Current Payables of BDT6.82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current Other Current Payables is BDT6.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT12.11, compared to a current price of BDT10.60 — trading 12.5% below its estimated fair value. The current Other Current Payables is BDT6.82 Mil. Central Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Other Current Payables is BDT6.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT10.60 is trading 12.5% below its estimated GF Value™ of BDT12.11. GuruFocus considers Central Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for DHA:CENTRALPHL:

  • Other Current Payables: BDT6.82 Mil
  • GF Value™: BDT12.11 vs. price of BDT10.60 (12.5% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
65GF Score

Get the complete analysis for DHA:CENTRALPHL

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT10.60
Price
BDT12.11
GF Value